IL309074A - Substances for the activation of serotonin receptors - Google Patents

Substances for the activation of serotonin receptors

Info

Publication number
IL309074A
IL309074A IL309074A IL30907423A IL309074A IL 309074 A IL309074 A IL 309074A IL 309074 A IL309074 A IL 309074A IL 30907423 A IL30907423 A IL 30907423A IL 309074 A IL309074 A IL 309074A
Authority
IL
Israel
Prior art keywords
compound
alkyl
hydrogen
formula
compounds
Prior art date
Application number
IL309074A
Other languages
English (en)
Hebrew (he)
Inventor
B Perni Robert
Short Glenn
Robert DIFRANCESCO Benjamin
KHAN Tanweer
Original Assignee
Entheogenix Biosciences Inc
Atai Therapeutics Inc
B Perni Robert
Short Glenn
Robert DIFRANCESCO Benjamin
KHAN Tanweer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entheogenix Biosciences Inc, Atai Therapeutics Inc, B Perni Robert, Short Glenn, Robert DIFRANCESCO Benjamin, KHAN Tanweer filed Critical Entheogenix Biosciences Inc
Publication of IL309074A publication Critical patent/IL309074A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C225/14—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated
    • C07C225/16—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C381/00—Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
    • C07C381/10—Compounds containing sulfur atoms doubly-bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/52—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups or amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/60—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/64—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
    • C07C217/66—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain
    • C07C217/70—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/38—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
    • C07C321/24—Thiols, sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
    • C07C321/28—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL309074A 2021-06-08 2022-06-08 Substances for the activation of serotonin receptors IL309074A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163208391P 2021-06-08 2021-06-08
US202163241662P 2021-09-08 2021-09-08
PCT/US2022/032715 WO2022261240A2 (en) 2021-06-08 2022-06-08 Dimethoxyphenylalkylamine activators of serotonin receptors

Publications (1)

Publication Number Publication Date
IL309074A true IL309074A (en) 2024-02-01

Family

ID=84426423

Family Applications (1)

Application Number Title Priority Date Filing Date
IL309074A IL309074A (en) 2021-06-08 2022-06-08 Substances for the activation of serotonin receptors

Country Status (11)

Country Link
US (3) US11926574B2 (enExample)
EP (1) EP4351548A4 (enExample)
JP (1) JP2024520832A (enExample)
KR (1) KR20240019157A (enExample)
AU (1) AU2022288926A1 (enExample)
BR (1) BR112023025599A2 (enExample)
CA (1) CA3216096A1 (enExample)
CL (1) CL2023003662A1 (enExample)
IL (1) IL309074A (enExample)
MX (1) MX2023014630A (enExample)
WO (1) WO2022261240A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023539113A (ja) 2020-08-18 2023-09-13 サイビン アイアールエル リミテッド フェネチルアミン誘導体、組成物およびその使用方法
JP2024520832A (ja) 2021-06-08 2024-05-24 エンセオジェニックス バイオサイエンシズ， インコーポレイテッド セロトニン受容体のジメトキシフェニルアルキルアミン活性化剤
CA3242479A1 (en) 2021-12-27 2023-07-06 Atai Therapeutics, Inc. AMINOTERALINE SEROTONIN RECEPTOR ACTIVATORS
JP2026513655A (ja) * 2022-10-28 2026-04-30 サイビン アイアールエル リミテッド フェネチルアミン化合物、組成物、及び使用方法
WO2024124056A1 (en) * 2022-12-07 2024-06-13 Entheogenix Biosciences, Inc. Novel sulfoximine activators of serotonin receptors
EP4637735A1 (en) * 2022-12-22 2025-10-29 ATAI Therapeutics, Inc. Dimethoxyphenyl heteroaromatic alkylamine activators of serotonin receptors
EP4637736A1 (en) * 2022-12-22 2025-10-29 ATAI Therapeutics, Inc. Prodrugs of dimethoxyphenylalkylamine activators of serotonin receptors
US12343319B2 (en) 2023-05-01 2025-07-01 Atai Therapeutics, Inc. Compositions and methods for treatment of diseases and disorders

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6045180B2 (ja) 1977-05-17 1985-10-08 第一製薬株式会社 ２−アミノテトラリン誘導体
ZA903906B (en) * 1989-05-25 1992-02-26 Takeda Chemical Industries Ltd Benzocycloalkane derivatives and production thereof
AU632809B2 (en) * 1989-05-25 1993-01-14 Takeda Chemical Industries Ltd. Benzocycloalkane benzopyran and benzothiopyran urea derivatives and production thereof
FR2691145A1 (fr) * 1992-05-18 1993-11-19 Inst Nat Sante Rech Med Nouveaux dérivés de la dihydroxybenzylamine, leur préparation et les compositions pharmaceutiques qui les contiennent.
US5807897A (en) 1996-03-01 1998-09-15 Zeneca Limited Aminotetralin derivative and compositions and method of use thereof
US6225352B1 (en) 1996-08-14 2001-05-01 Warner-Lambert Company Low molecular weight dendritic compounds as pharmaceutical agents
NZ510988A (en) 1998-10-07 2005-01-28 Ortho Mcneil Pharm Inc N-aralkylaminotetralins useful as ligands for the neuropeptide Y5 receptor
HUP0202143A3 (en) 1999-07-28 2003-12-29 Ortho Mcneil Pharm Inc Amine and amide derivatives as ligands for the neuropeptide y y5 receptor pharmaceutical compositions containing them and their use
DE10007948A1 (de) 2000-02-22 2001-09-06 Wella Ag Mittel zur Färbung von Fasern
FR2809396B1 (fr) 2000-05-24 2005-10-14 Centre Nat Rech Scient Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
ES2566056T3 (es) 2001-03-29 2016-04-08 Eli Lilly And Company N-(2-ariletil)bencilaminas como antagonistas del receptor 5-HT6
US20050152858A1 (en) 2003-07-11 2005-07-14 Isp Investments Inc. Solubilizing agents for active or functional organic compounds
US20070196395A1 (en) 2003-12-12 2007-08-23 Mackerell Alexander Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
US9101613B2 (en) 2006-02-15 2015-08-11 Neurim Pharmaceuticals (1991) Ltd. Methods for treating neurological disease
MX2008015843A (es) 2006-06-20 2009-01-09 Hoffmann La Roche Derivados de tetralina e indano y usos de los mismos.
US20080248511A1 (en) 2007-03-26 2008-10-09 Promega Corporation Methods to quench light from optical reactions
CA2686994A1 (en) 2007-05-11 2008-11-20 Mpex Pharmaceuticals, Inc. Polybasic bacterial efflux pump inhibitors and therapeutic uses thereof
BRPI0919920A2 (pt) 2008-10-22 2016-02-16 Acucela Inc compostos para tratamento de doenças e desordens oftálmicas
US20120283298A1 (en) 2009-10-16 2012-11-08 Albert Michael Crider Methods for treating memory impairment
EP2418196A1 (en) 2010-07-29 2012-02-15 IMTM GmbH Dual alanyl-aminopeptidase and dipeptidyl-peptidase IV inhibitors
GB201409516D0 (en) * 2014-05-29 2014-07-16 Randox Lab Ltd Immunoassay for compounds of the NBOMe family
US10454900B2 (en) 2015-09-25 2019-10-22 Mcafee, Llc Remote authentication and passwordless password reset
WO2018094005A1 (en) 2016-11-16 2018-05-24 The General Hospital Corporation Myeloperoxidase imaging agents
EP3700935A4 (en) 2017-10-25 2021-08-04 University Of South Florida INGREDIENT-INDUCED ACTIVATION OF THE REELIN SIGNALING SYSTEM
CA3079819C (en) 2017-11-06 2023-03-14 Acelot, Inc. Small molecule drugs and related methods for treatment of diseases related to a.beta.42 oligomer formation
WO2019099402A1 (en) 2017-11-14 2019-05-23 Rutgers, The State University Of New Jersey Therapeutic compounds and methods to treat infection
AU2018379992B2 (en) 2017-12-05 2022-07-21 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
EP3841085B1 (en) * 2018-08-22 2026-05-06 University Of Technology Sydney Nbome test
US12318357B2 (en) 2019-08-02 2025-06-03 Acelot, Inc. Small molecule drugs and related methods for treatment of diseases related to TDP-43, alpha-synuclein, huntingtin's protein and tau protein oligomer formation
US11660305B2 (en) 2019-11-19 2023-05-30 Turtle Bear Holdings, Llc Tryptamine compositions for enhancing neurite outgrowth
US12534425B2 (en) 2020-06-29 2026-01-27 Gilgamesh Pharmaceuticals, Inc. Phenalkylamines and methods of treating mood disorders
DK4172145T3 (da) 2020-06-30 2026-07-20 Reunion Neuroscience Inc Tryptamin-prodrugs som serotonin-receptor-aktivatorer til behandling af f.eks. depression
JP2024512796A (ja) 2021-04-01 2024-03-19 テラン バイオサイエンシーズ インク． サイケデリック薬およびセロトニン受容体調節因子に関する方法と組成物
CA3217737A1 (en) 2021-05-11 2022-11-17 Jason WALLACH Selective, partial, and arrestin-biased 5-ht2a agonists with utility in various disorders
JP2024520832A (ja) 2021-06-08 2024-05-24 エンセオジェニックス バイオサイエンシズ， インコーポレイテッド セロトニン受容体のジメトキシフェニルアルキルアミン活性化剤
WO2022261263A1 (en) 2021-06-08 2022-12-15 Gilgamesh Pharmaceuticals, Inc. Methods of treating neuropsychiatric disorders
MX2024007220A (es) 2021-12-15 2024-08-27 Delix Therapeutics Inc Psicoplastogenos de pirrolidina fusionada y sus usos.
CA3242479A1 (en) 2021-12-27 2023-07-06 Atai Therapeutics, Inc. AMINOTERALINE SEROTONIN RECEPTOR ACTIVATORS
WO2024124056A1 (en) 2022-12-07 2024-06-13 Entheogenix Biosciences, Inc. Novel sulfoximine activators of serotonin receptors
EP4637736A1 (en) 2022-12-22 2025-10-29 ATAI Therapeutics, Inc. Prodrugs of dimethoxyphenylalkylamine activators of serotonin receptors
EP4637735A1 (en) 2022-12-22 2025-10-29 ATAI Therapeutics, Inc. Dimethoxyphenyl heteroaromatic alkylamine activators of serotonin receptors
WO2024192150A2 (en) 2023-03-16 2024-09-19 Atai Therapeutics Inc. 3-alkylamine indole activators of serotonin receptors
US12343319B2 (en) 2023-05-01 2025-07-01 Atai Therapeutics, Inc. Compositions and methods for treatment of diseases and disorders

Also Published As

Publication number Publication date
AU2022288926A1 (en) 2023-10-19
CL2023003662A1 (es) 2024-05-03
WO2022261240A2 (en) 2022-12-15
US12351537B2 (en) 2025-07-08
US11926574B2 (en) 2024-03-12
CA3216096A1 (en) 2022-12-15
WO2022261240A3 (en) 2023-01-05
MX2023014630A (es) 2024-01-30
EP4351548A4 (en) 2025-04-30
US20230138118A1 (en) 2023-05-04
US20250282712A1 (en) 2025-09-11
US20240294461A1 (en) 2024-09-05
BR112023025599A2 (pt) 2024-02-20
JP2024520832A (ja) 2024-05-24
KR20240019157A (ko) 2024-02-14
EP4351548A2 (en) 2024-04-17

Similar Documents

Publication Publication Date Title
US20230117791A1 (en) SUBSTITUTED 1,2,3,4,5,6-HEXAHYDROAZEPINO[4,5-b]INDOLES FOR TREATING BRAIN DISORDERS
US12351537B2 (en) Dimethoxyphenylalkylamine activators of serotonin receptors
US10106502B2 (en) Direct inhibitors of Keap1-Nrf2 interaction as antioxidant inflammation modulators
IL278281B1 (en) Crystal form of c-met inhibitor and salt form thereof and preparation method therefor
CN118221685A (zh) 作为kras g12d抑制剂的吲哚类化合物
JP2024547131A (ja) セロトニン受容体のアミノテトラリン活性化剤
MX2011012712A (es) Derivados de carboxamida sustituidos con arilo como bloqueadores del canal de calcio o sodio.
IL266126A (en) Pyridone compound as a c – met inhibitor
IL309210A (en) Parent drugs and conjugates of dimethyltryptamine
Liu et al. Design, synthesis and evaluation of vilazodone-tacrine hybrids as multitarget-directed ligands against depression with cognitive impairment
IL267968A (en) Selective hdac6 inhibitors, a method for their preparation and application
IL319273A (en) A series of bridged nitrogen-containing heterocyclic compounds and a method for their preparation
IL259297B (en) Heterocyclic compounds for the treatment of disease
IL274773B2 (en) A pyrimidine sulfamide derivative and a method of its preparation and medical application
US6852730B2 (en) Substituted fused pyrazolecarboxylic acid arylamides and related compounds
EP4624470A1 (en) Yohimbine derivative, and preparation method therefor and pharmaceutical composition and use thereof
JP2005516901A (ja) １Ｈ−ピロロ［３，２−ｂ］ピリジン−３−カルボン酸アミド化合物
WO2024026568A1 (en) Fused heterocyclic mescaline derivatives
IL272366B (en) Adamantylmethylamine derivatives and their uses as a pharmaceutical preparation
CN117500487A (zh) 血清素受体的二甲氧基苯基烷基胺激活剂
Qin et al. Discovery of New N-H Aporphine Derivatives As Brain-Penetrant Gq-Biased 5-HT2C Receptor Agonists and Dual 5-HT2C/5-HT2A Receptor Agonists
WO2024217513A1 (zh) β-catenin/BCL9蛋白-蛋白相互作用抑制剂及其制备方法和应用
Katzman Navigating the Roads to Drug Discovery Part 1: Design, Synthesis, and Biological Evaluation of a Novel Class of Allosteric Modulators of N-Methyl-D-Aspartate Receptor Function Part 2: Discovery of Novel Tetrahydroisoquinoline (THIQ)-Based CXCR4 Antagonists and Conformational Analysis of Structurally Similar CXCR4 Antagonists